Acumen Pharmaceuticals Inc (ABOS) Stock Price, Quote & News

Company Profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for t...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 344 4190

Website: acumenpharm.com

Address:

1210-1220 Washington St., Suite 210, Newton, United States

Johndoe456 Jul. 20 at 3:55 PM

$ABOS $CMPX I LIKE 💰

0 · Reply

Lofticus Jul. 15 at 4:26 PM

$ABOS

1 · Reply

bhavn008 Jul. 15 at 4:09 PM

$ABOS : Acumen Pharmaceuticals (NASDAQ: ABOS) announced a strategic deal with JCR Pharma today, to enhance brain delivery of its Alzheimer’s drug sabirnetug using J-Brain Cargo tech, with up to $555M in milestones and royalties. Sabirnetug, targeting toxic Aβ oligomers, is in Phase 2 (ALTITUDE-AD, enrolled March 2025, topline data late 2026) with low ARIA (7% in Phase 1) and strong target engagement. The deal addresses blood brain barrier, BBB limitations (only ~1% penetration for mAbs), de-risks pipeline, expands to next-gen variants, and provides non-dilutive funding amid $198M cash runway to 2027. Far from low confidence, it signals high belief in sabirnetug’s potential, strategic enhancement for better efficacy/safety in the $15B Alzheimer’s disease, AD market. Long ABOS. Not investment advice. #biotech #stocks #healthcare

1 · Reply

401stprophet Jul. 15 at 3:43 PM

$ABOS what are the thoughts on significant volume spike?

1 · Reply

CivilEngineer2444 Jul. 15 at 12:24 PM

$ABOS This is a materially positive development—providing a potential technical advantage and roadmap with multiple catalysts. Keep

0 · Reply

leon_dedrick Jul. 15 at 11:10 AM

$ABOS I dont short stocks.......but im sure this is going under .75 cents or lower today

2 · Reply

MHM7700 Jul. 15 at 11:07 AM

21% win on $ABOS to start the day. all PTs hit perfectly. PT1 @ 1.60 (25% covered), PT2 @ 1.55 (25% covered) and PT3 @ 1.45 (50% covered). https://stocktwits.com/MHM7700/message/620962773

0 · Reply

leon_dedrick Jul. 15 at 11:07 AM

$ABOS Did they get the news backwards because JCR is a 80 billion dollar company Why would the small 90 million dollar company pay the 80 billion dollar company???

1 · Reply

RealSituation Jul. 15 at 11:05 AM

$ABOS Crazy

1 · Reply

leon_dedrick Jul. 15 at 11:04 AM

$ABOS 😂 Like how they released the PR in sessions I was so fast selling this, thst i only lost 12 dollars 😂

0 · Reply

JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform

Jul 10, 2025, 8:00 AM EDT - 13 days ago

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025

May 13, 2025, 10:11 AM EDT - 2 months ago

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:00 PM EDT - 2 months ago

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

May 6, 2025, 4:00 PM EDT - 2 months ago

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 2, 2025, 7:00 AM EDT - 4 months ago

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

Mar 27, 2025, 10:05 AM EDT - 4 months ago

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 4:00 PM EDT - 4 months ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

Mar 18, 2025, 8:48 AM EDT - 4 months ago

Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's

Mar 12, 2025, 8:00 AM EDT - 4 months ago

Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting

Mar 10, 2025, 4:00 PM EDT - 4 months ago

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

Nov 26, 2024, 4:00 PM EST - 8 months ago

Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 12, 2024, 1:17 PM EST - 9 months ago

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:00 PM EST - 9 months ago

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Nov 6, 2024, 4:00 PM EST - 9 months ago

Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference

Oct 31, 2024, 8:05 AM EDT - 9 months ago

Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference

Oct 23, 2024, 8:00 AM EDT - 9 months ago

Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 15, 2024, 8:00 AM EDT - 10 months ago

Lucy Therapeutics Appoints Kim Drapkin as Board Chair

LENZ

Sep 30, 2024, 4:00 PM EDT - 10 months ago

Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

Sep 25, 2024, 4:00 PM EDT - 10 months ago

Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

Sep 3, 2024, 4:00 PM EDT - 11 months ago

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference

Aug 13, 2024, 11:17 AM EDT - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024

Jul 29, 2024, 8:38 PM EDT - 1 year ago

Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer's Disease

Jul 28, 2024, 7:30 AM EDT - 1 year ago

Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC®) 2024

May 14, 2024, 12:46 PM EDT - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

May 13, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 8, 2024, 5:47 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

May 8, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease

May 7, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

Apr 16, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

Apr 4, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease

Mar 26, 2024, 10:45 AM EDT - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

Mar 19, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

Mar 12, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days

Mar 8, 2024, 8:50 AM EST - 1 year ago

Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting

Feb 21, 2024, 8:00 AM EST - 1 year ago

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting

Feb 1, 2024, 7:00 AM EST - 1 year ago

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

Jan 4, 2024, 4:15 PM EST - 1 year ago

Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 13, 2023, 4:29 PM EST - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 7:00 AM EST - 1 year ago

Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

Nov 13, 2023, 7:00 AM EST - 1 year ago

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 6, 2023, 4:01 PM EST - 1 year ago

Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023

Nov 6, 2023, 7:30 AM EST - 1 year ago

Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology

Nov 2, 2023, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference

Oct 4, 2023, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's During Symposium at the 16th Annual Clinical Trials on Alzheimer's Disease (CTAD)

Oct 3, 2023, 11:03 AM EDT - 1 year ago

Navigating Acumen's Alzheimer's Risk And Reward

Johndoe456 Jul. 20 at 3:55 PM

$ABOS $CMPX I LIKE 💰

0 · Reply

Lofticus Jul. 15 at 4:26 PM

$ABOS

1 · Reply

bhavn008 Jul. 15 at 4:09 PM

1 · Reply

401stprophet Jul. 15 at 3:43 PM

$ABOS what are the thoughts on significant volume spike?

1 · Reply

CivilEngineer2444 Jul. 15 at 12:24 PM

$ABOS This is a materially positive development—providing a potential technical advantage and roadmap with multiple catalysts. Keep

0 · Reply

leon_dedrick Jul. 15 at 11:10 AM

$ABOS I dont short stocks.......but im sure this is going under .75 cents or lower today

2 · Reply

MHM7700 Jul. 15 at 11:07 AM

21% win on $ABOS to start the day. all PTs hit perfectly. PT1 @ 1.60 (25% covered), PT2 @ 1.55 (25% covered) and PT3 @ 1.45 (50% covered). https://stocktwits.com/MHM7700/message/620962773

0 · Reply

leon_dedrick Jul. 15 at 11:07 AM

$ABOS Did they get the news backwards because JCR is a 80 billion dollar company Why would the small 90 million dollar company pay the 80 billion dollar company???

1 · Reply

RealSituation Jul. 15 at 11:05 AM

$ABOS Crazy

1 · Reply

leon_dedrick Jul. 15 at 11:04 AM

$ABOS 😂 Like how they released the PR in sessions I was so fast selling this, thst i only lost 12 dollars 😂

0 · Reply

MHM7700 Jul. 15 at 11:03 AM

$ABOS short @ 1.84. PT1 @ 1.60, PT2 @ 1.55 and PT3 @ 1.50 (or ride the trend). SL @ 2.00.

1 · Reply

pablo4 Jul. 14 at 7:35 PM

$ABOS I have a large position accumulated way below company cash/share....average in the low 1s and well in-the-money now. I love how ABOS announced its upcoming presentation well in advance leaving a lot of time to speculate. It's presentation was announced last week on July 10 but won't be made until July 28....2 weeks from now. And the biotech market is strengthening after years of malaise. IMO

0 · Reply

makedatbread88 Jul. 11 at 7:54 PM

$ABOS unusual volume here today too and 1 week chart looking good

0 · Reply

SmartMoneyTradez Jul. 11 at 7:50 PM

$ABOS Something is going on here? Volume , no news or pumpers. Just how I like it.

0 · Reply

Geohotventures Jul. 11 at 6:39 PM

$ABOS what's cookin'?

0 · Reply

BigSqueezeComing Jul. 10 at 12:25 PM

$ABOS Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC) 2025 By Acumen Pharmaceuticals, Inc. | July 10, 2025, 8:00 AM

0 · Reply

Thekiss320 Jun. 26 at 12:45 PM

$ABOS LET’S GO🚀

0 · Reply

vaselineguy Jun. 24 at 3:11 AM

$ABOS still here

0 · Reply

Thekiss320 Jun. 23 at 7:57 PM

$ABOS

0 · Reply

JarvisFlow Jun. 17 at 12:00 PM

Citigroup has updated their rating for Acumen Pharmaceuticals ( $ABOS ) to Buy with a price target of 4.

0 · Reply

PenkeTrading Jun. 10 at 1:37 PM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Acumen Pharmaceuticals Inc. Is that bullish or bearish? $ABOS #Acumen #RsiOverbought #NASDAQ

0 · Reply

DougieFreshPicks Jun. 9 at 11:39 PM

$ABOS on the list 👍

0 · Reply

Market Cap	93.89M
Revenue (ttm)	0.00
Net Income (ttm)	-102.33M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.19

Volume	258,404
Avg Vol	489,180
Day's Range	N/A - N/A
Shares Out	60.57M
Stochastic %K	92%
Beta	0.11
Analysts	Strong Sell
Price Target	$7.80